Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Voir plus

December 1st, 2020

Biophytis is participating to:
– The Geneva European Midcap digital event, December 1rst & 2 2020
– The “Anticovid” Biotech sector conference organized by the SFAF on Wednesday, December 9
– The 13th International SCWD virtual conference, December 11-13 2020

November 20, 2020

Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute with NEGMA. Read the Press Release

Our science

Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.

See more

Pipeline

Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

See more

Investors

BIOPHYTIS ON THE STOCK MARKET

Biophytis has been listed on the market Euronext Growth Paris
since July 13, 2015.

ISIN : FR0012816825
Ticker: ALBPS
Type of listing : continuous
Number of outstanding shares: 99 803 351  (as of November 30, 2020)
Eligible for PEA and PEA-PME equity saving plans

Click here for live stock price

See more